Kazia says Sovargen doses first patient in Phase 1b/2a paxalisib trial for rare seizure disorders, triggers $2 million payment

Bitget2026/09/22 11:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Sovargen dosed the first patient in a Phase 1b/2a trial of paxalisib for rare, treatment-resistant seizure disorders.
No clinical results have been presented; data are expected later as enrollment and study follow-up continue.
The start of dosing triggered a USD 2 million development milestone payment to Kazia under a 2024 licensing deal.
The agreement shifts epilepsy development and commercialization to Sovargen in most markets, creating potential milestones up to USD 17 million.
Kazia retains paxalisib’s main clinical focus in oncology while the partner tests the drug’s potential in neurological indications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kazia Therapeutics Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609220730PR_NEWS_USPR_____NY51650) on September 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Kazia says Sovargen doses first patient in Phase 1b/2a paxalisib trial for rare seizure disorders, triggers $2 million payment

You may also like

Crypto prices